AI Summary7 Jul 202622 Muharram 1448 AH
AI Summary
7 Jul 202622 Muharram 1448 AH
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine has advanced to Phase III clinical trials for an AI-identified drug to treat idiopathic pulmonary fibrosis (IPF). The drug, known as Rintoseratib, targets the disease's underlying mechanisms and shows promising results, improving breathing capacity by an average of 98.4 mL in the treatment group. The company received 'orphan drug' designation from the U.S. FDA in February 2023.
These developments are based on the company's Pharma.AI system, which integrates vast biological data to identify therapeutic targets.
Follow these topics
Sign in to follow the topics that matter to you
This summary is generated with AI and receives periodic editorial review. Refer to the original source for full details.
Insilico Medicine advances AI drug for IPF to Phase III trials
Insilico Medicine has advanced to Phase III clinical trials for an AI-identified drug to treat idiopathic pulmonary fibrosis (IPF). The drug, known as Rintoseratib, targets the disease's underlying mechanisms and shows promising results, improving breathing capacity by an average of 98.4 mL in the treatment group. The company received 'orphan drug' designation from the U.S. FDA in February 2023.
These developments are based on the company's Pharma.AI system, which integrates vast biological data to identify therapeutic targets.
Business
Follow these topics
Sign in to follow the topics that matter to you
This summary is generated with AI and receives periodic editorial review. Refer to the original source for full details.
0
0 reading now
Insight Score
Rate to unlock
You have not rated yet.
Sign in to react, rate, and save. Sign In
